Targeted Agent

PreclinicalSmall molecule

Targeted Agent is one of 65 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerActive, not recruiting

Colorectal CancerActive, not recruiting

Non-Small Cell Lung CancerPreclinical

Active, not recruiting

Colorectal CancerPreclinical

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Gemzar

GGynecologic Oncology Group

Preclinical

72 2

PORTRAZZA

Eli Lilly

Preclinical

8 3

Imjudo

AstraZeneca

Preclinical

5 4

Gilotrif

Boehringer Ingelheim

Preclinical

12 5

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 6

Remeron

OOrganon and Co

Preclinical

1 7

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 8

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—9

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—10

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2031

Phase 1/2Recruiting

Malignancies

NCT05674825

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Differences in Rate of Decline in CT-defined Skeletal Muscle Mass and Physical Performance in Patients With Advanced Non-small Cell Lung Cancer Receiving Chemotherapy and Targeted Therapy/Immunotherapy, Before and After Treatment.

Recruiting·PPrince of Songkla University··NCT06326086·240 enrolled

Colorectal Cancer1 trial

Chemotherapy Alone Versus Chemotherapy Plus Targeted Therapy as Adjuvant Therapy for Initially Unresectable Colorectal Cancer Liver Metastases

Completed·FFudan University··NCT06027775·198 enrolled

Malignancies1 trial

Investigation of Profile-related Evidence Determining Individualized Cancer Therapy for Patients With Aggressive Malignancies and Poor Prognoses

Recruiting·MMedical College of Wisconsin·Phase 1/2·NCT05674825·400 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Targeted Agent. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Targeted Agent compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Targeted Agent. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Prince of Songkla University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: PPrince of Songkla University

Targeted Agent

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2031

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Colorectal Cancer1 trial

Malignancies1 trial

References

Drug Info

Quick Facts

Related News